Clinical Trials Logo

Brain Neoplasms clinical trials

View clinical trials related to Brain Neoplasms.

Filter by:

NCT ID: NCT00063973 Completed - Clinical trials for Recurrent Childhood Ependymoma

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Start date: July 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.

NCT ID: NCT00062478 Completed - Brain Neoplasms Clinical Trials

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

Start date: October 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.

NCT ID: NCT00054795 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Start date: n/a
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain radiation therapy alone.

NCT ID: NCT00052780 Completed - Clinical trials for Recurrent Childhood Ependymoma

Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors

Start date: October 2002
Phase: Phase 1
Study type: Interventional

Phase I trial to study the safety of combining O6-benzylguanine with temozolomide in treating children who have recurrent or refractory brain tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. O6-benzylguanine may increase the effectiveness of temozolomide by making tumor cells more sensitive to the drug.

NCT ID: NCT00049127 Completed - Clinical trials for Adult Anaplastic Oligodendroglioma

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

Start date: June 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of imatinib mesylate and to see how well it works in treating patients with a recurrent brain tumor that has not responded to previous surgery and radiation therapy. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

NCT ID: NCT00042445 Completed - Leukemia Clinical Trials

Brain Neoplasms, Leukemia and Petrochemical Exposures

Start date: August 2000
Phase: N/A
Study type: Observational

The aim of this study is to examine the association of exposure to air contaminants (PAH & VOC) emitted from the petrochemical industries, specific genetic polymorphisms (P4501A1 (MspI & exon 7) and GSTM1 & T1) of study subjects and their parents, and the risks of brain tumors and leukemia among children and youths in metropolitan Kaohsiung, southern Taiwan.

NCT ID: NCT00042367 Completed - Brain Tumors Clinical Trials

Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors

BB'98
Start date: April 4, 2000
Phase: N/A
Study type: Interventional

The purposes of this study are to find the highest dose of mafosfamide that can be given without causing severe side effects, to see how well the combination of these chemotherapy drugs and lower doses of radiation work to delay or stop the growth of the tumor, and to evaluate the pharmacokinetics (how the body handles) of Mafosfamide.

NCT ID: NCT00040573 Completed - Glioma Clinical Trials

Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.

Start date: June 2002
Phase: Phase 1/Phase 2
Study type: Interventional

This drug is being developed to treat a type of brain cancer, glioma. This study was designed to determine a safe and well tolerated dose. Patients must have had prior treatment for their glioma and be eligible for removal of their recurring tumor.

NCT ID: NCT00038441 Completed - Glioma Clinical Trials

Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas

Start date: September 1995
Phase: Phase 1/Phase 2
Study type: Interventional

This is a clinical research study of a new investigational treatment for cancer called "DTI-015" to be given by intratumoral injection. Intratumoral injection is when drug is injected directly into the tumor. This study will help doctors find out what is the best dose level for DTI-015 and if this treatment can shrink tumors without causing severe side effects. The effects of the drug on the patient's quality of life (how the patient feels and what the patient can do) and their mental functions (reasoning and thinking abilities) will also be studied.

NCT ID: NCT00019630 Completed - Brain Tumor Clinical Trials

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

Start date: July 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have refractory solid tumors.